Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Jette – page 22

260 clinical trials in Jette, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Jette at a glance
260
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

260 trials in Jette

Open in trial search

Crohn's disease

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Study on Valaciclovir to Prevent Congenital CMV Infection in Pregnant Women with First Trimester CMV Infections

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Valaciclovir
  • Sponsor:UZ Leuven

Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-501A
  • Sponsor:Allogene Therapeutics Inc.

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Belgian Society Of Medical Oncology

Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Jette

What the registry says about research in the country

01 Oncology Research

Clinical investigations focusing on innovative treatments for various cancers, including non-small cell lung cancer, melanoma, and colorectal cancer. Studies are evaluating new combination therapies and targeted treatments to improve patient outcomes.

  • Lung cancer therapeutics
  • Melanoma treatments
  • Pediatric liver tumors

Advanced clinical trials exploring immunotherapy combinations and targeted molecular approaches.

02 Metabolic Disorders

Research focusing on treatments for diabetes and obesity, including innovative therapies for both Type 1 and Type 2 diabetes. Studies are evaluating new medications for weight management and metabolic control.

  • Type 1 diabetes interventions
  • Obesity management
  • Weight maintenance in adolescents

Comprehensive trials investigating metabolic disease management and treatment outcomes.

03 Neurological Conditions

Studies examining treatments for status epilepticus and Alzheimer's-related psychosis. Research includes innovative approaches to managing neurological complications following cardiac arrest.

  • Post-cardiac arrest care
  • Alzheimer's disease complications
  • Seizure management

Advanced clinical research focusing on improving neurological outcomes and patient care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.